出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2023年4月
医薬品受託製造市場 : サービス［医薬品（API、FDF – 錠剤、カプセル、注射剤）、生物学的製剤（API、FDF）、医薬品開発］、エンドユーザー（大手製薬会社、中小製薬会社、ジェネリック製薬会社） – 2028年までの世界予測
Pharmaceutical Contract Manufacturing Market by Service (Pharmaceutical (API, FDF – Tablet, Capsule, Injectable)), Biologic (API, FDF), Drug Development), End User (Big Pharma, Small & Medium-sized Pharma, Generic Pharma) – Global Forecast to 2028
| ページ数 | 279 |
| 図表数 | 291 |
| 種別 | 英文調査報告書 |
| 価格 |
The global pharmaceutical contract development and manufacturing market size is projected to reach USD 258.3 billion by 2028 from USD 176.5 billion in 2023, at a CAGR of 7.9% during the forecast period. Factors such as increasing demand for generics due to their low cost and the looming patent expiry of blockbuster medications have pushed companies to focus on core functions, supporting the demand for CDMO services, and driving the market growth at a faster pace.
“The biologic manufacturing service segment is likely to grow at the highest CAGR during the forecast period of 2023-2028.”
On the basis of service, the pharmaceutical contract development and manufacturing market is segmented into pharmaceutical manufacturing service, drug development service, and biologic manufacturing service. The biologic manufacturing service segment is projected to grow at the highest CAGR during the forecast period. The growth is attributed to the rising demand for biologics, targeted drug therapies, and increase in the number cell & gene therapy pipeline studies. These factors are likely to have a positive impact on segmental growth.
“The big pharmaceutical companies segment is likely to grow at the highest CAGR during the forecast period of 2023-2028.”
Based on end user, the pharmaceutical contract development and manufacturing market is segmented into big pharmaceutical companies, small and midsized pharmaceutical companies, generic pharmaceutical companies, and other end users (Academic Institutes, Small CDMOs, and CROs). The big pharmaceutical companies segment held a dominant share of the pharmaceutical contract development and manufacturing market, in 2022. The large share of this segment is attributed to the growing focus of pharma giants on core activities like increasing R&D for the discovery & development of new molecules, pushing them to outsource the manufacturing services. This is one of the major factors anticipated to project market growth.
“Asia Pacific region is likely to grow at a faster pace.”
The pharmaceutical contract development and manufacturing market is divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America accounted for the dominant share of the pharmaceutical contract development and manufacturing market. The dominance of the region is attributable to various factors such as the presence of leading players in the region coupled with the ongoing research activities of pharmaceutical contract development and manufacturing. Asia Pacific region is likely to grow at a faster pace owing to various factors such as the growing awareness of personalized therapeutics, rising government initiatives for generic medicines in the region, and the emergence of new market players in the pharmaceutical contract development and manufacturing market.
The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 60%, and Demand Side – 40%
• By Designation (Supply Side): Managers – 45%, CXOs & Directors – 25%, Executives- 15%, Other -15.0%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%
Lists of Companies Profiled in the Report:
• Thermo Fisher Scientific, Inc. (US)
• Catalent, Inc. (US)
• Lonza Group (Switzerland)
• AbbVie, Inc. (US)
• WuXi AppTec (China)
• Evonik Industries AG (Germany)
• Samsung Biologics. (South Korea)
• Boehringer Ingelheim International GmbH. (Germany)
• Siegfried Holding AG (Switzerland)
• Piramal Pharma Solutions (India)
• Recipharm AB. (Sweden)
• Eurofins Scientific (Luxembourg)
• FUJIFILM Holdings Corporation (Japan)
• Almac Group (UK)
• Vetter Pharma (Germany)
• Delpharm Holdings (France)
• Yuhan Corporation (South Korea)
• Curia Global, Inc. (US)
• Charles River Laboratories. (US)
• Lannett Company, Inc. (US)
• Cambrex Corporation. (US)
• FAMAR Healthcare Services (France)
• Biocon Limited (India)
• Sai Life Sciences Limited (India)
• PCI Pharma Services (US).
Research Coverage:
This report provides a detailed picture of the pharmaceutical contract development and manufacturing market. It aims at estimating the size and future growth potential of the market across different segments, such as service, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall pharmaceutical contract development and manufacturing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (Increased investment in precision medicines, Patent expiry & increasing demand for generic drugs, High cost of in-house drug development, Investments in advanced manufacturing technologies by CDMOs), restraints (Varying regulatory requirements across various regions), opportunities (Rising demand for cell & gene therapies, Growing inclination toward one-stop-shop model, Market expansion in emerging countries, Growth of nuclear medicine), and challenges (Introduction of serialization, Intellectual property risk) influencing the growth of pharmaceutical contract development and manufacturing market.
• Service Development/Innovation: Detailed insights on newly launched services, and technological assessment of the pharmaceutical contract development and manufacturing market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the pharmaceutical contract development and manufacturing market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the pharmaceutical contract development and manufacturing market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), Lonza Group (Switzerland), AbbVie, Inc. (US), WuXi AppTec (China) and among others in the pharmaceutical contract development and manufacturing market.
目次
1 INTRODUCTION 36
1.1 STUDY OBJECTIVES 36
1.2 MARKET DEFINITION 36
1.2.1 INCLUSIONS AND EXCLUSIONS 36
1.3 MARKET SCOPE 37
1.4 YEARS CONSIDERED 37
1.5 CURRENCY CONSIDERED 38
1.6 STAKEHOLDERS 38
1.7 LIMITATIONS 38
1.8 SUMMARY OF CHANGES 39
1.9 RECESSION IMPACT 39
2 RESEARCH METHODOLOGY 40
2.1 RESEARCH DATA 40
FIGURE 1 RESEARCH DESIGN 40
2.1.1 SECONDARY DATA 41
2.1.2 PRIMARY DATA 42
FIGURE 2 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: BREAKDOWN OF PRIMARIES 42
2.2 MARKET SIZE ESTIMATION 43
FIGURE 3 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022 43
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022 44
FIGURE 5 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE ANALYSIS, 2022 44
2.2.1 INSIGHTS FROM PRIMARIES 46
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS 46
2.2.2 SEGMENT ASSESSMENT (BY SERVICE AND END USER) 46
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 46
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 47
FIGURE 8 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: CAGR PROJECTIONS, 2023–2028 47
FIGURE 9 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES 48
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 49
FIGURE 10 DATA TRIANGULATION METHODOLOGY 49
2.5 RESEARCH ASSUMPTIONS 50
2.6 RISK ANALYSIS 50
2.7 IMPACT ANALYSIS OF RECESSION ON PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 50
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024–2027 (% GROWTH) 51
TABLE 2 US HEALTH EXPENDITURE, 2019–2027 (USD MILLION) 51
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 51
3 EXECUTIVE SUMMARY 52
FIGURE 11 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2023 VS. 2028 (USD BILLION) 52
FIGURE 12 BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2023 VS. 2028 (USD BILLION) 53
FIGURE 13 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2023 VS. 2028 (USD BILLION) 53
FIGURE 14 GEOGRAPHICAL SNAPSHOT: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 54
4 PREMIUM INSIGHTS 56
4.1 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET OVERVIEW 56
FIGURE 15 RISING INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET GROWTH 56
4.2 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE & COUNTRY (2022) 57
FIGURE 16 PHARMACEUTICAL MANUFACTURING SERVICES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022 57
4.3 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2023 VS. 2028 (USD BILLION) 58
FIGURE 17 PHARMACEUTICAL MANUFACTURING SERVICES SEGMENT TO DOMINATE MARKET TILL 2028 58
4.4 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SHARE, BY END USER, 2022 58
FIGURE 18 BIG PHARMACEUTICAL COMPANIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 58
4.5 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 59
FIGURE 19 ASIA PACIFIC TO REGISTER HIGHEST GROWTH FROM 2023 TO 2028 59
5 MARKET OVERVIEW 60
5.1 INTRODUCTION 60
5.2 MARKET DYNAMICS 60
FIGURE 20 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 60
TABLE 4 PHARMACEUTICAL CONTRACT MANUFACTURING AND DEVELOPMENT MARKET: IMPACT ANALYSIS 61
5.2.1 DRIVERS 61
5.2.1.1 Increased investment in precision medicines 61
5.2.1.2 Patent expiry & increasing demand for generic drugs 62
TABLE 5 IMPENDING PATENT EXPIRY OF BLOCKBUSTER DRUGS, BY YEAR 62
5.2.1.3 High cost of in-house drug development 62
FIGURE 21 AVERAGE COST OF DEVELOPING PHARMACEUTICAL COMPOUNDS FROM DISCOVERY TO LAUNCH, 2010–2020 (USD BILLION) 63
5.2.1.4 Investments in advanced manufacturing technologies by CDMOs 63
5.2.2 RESTRAINTS 64
5.2.2.1 Varying regulatory requirements across regions 64
5.2.3 OPPORTUNITIES 64
5.2.3.1 Rising demand for cell & gene therapy 64
TABLE 6 EXPANSIONS BY TOP COMPANIES IN 2022 64
5.2.3.2 Growing inclination toward one-stop-shop model 65
5.2.3.3 Market expansion in emerging countries 65
5.2.3.4 Growth of nuclear medicine 66
5.2.4 CHALLENGES 66
5.2.4.1 Introduction of serialization 66
5.2.4.2 Intellectual property risk 67
5.3 VALUE CHAIN ANALYSIS 67
FIGURE 22 VALUE CHAIN ANALYSIS: API PRODUCTION AND FORMULATION ADD MAXIMUM VALUE 68
5.4 ECOSYSTEM ANALYSIS 68
FIGURE 23 ECOSYSTEM ANALYSIS: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 68
TABLE 7 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: ROLE IN ECOSYSTEM 69
5.5 TECHNOLOGY ANALYSIS 70
5.6 PORTER’S FIVE FORCES ANALYSIS 71
TABLE 8 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: PORTER’S FIVE FORCES ANALYSIS 71
5.6.1 THREAT OF NEW ENTRANTS 71
5.6.2 THREAT OF SUBSTITUTES 71
5.6.3 BARGAINING POWER OF SUPPLIERS 71
5.6.4 BARGAINING POWER OF BUYERS 72
5.6.5 INTENSITY OF COMPETITIVE RIVALRY 72
5.7 REGULATORY ANALYSIS 72
TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72
TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 73
TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 73
TABLE 12 ROW: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74
TABLE 13 REGULATORY SCENARIO IN DIFFERENT COUNTRIES 74
5.8 KEY CONFERENCES & EVENTS, 2022–2023 77
TABLE 14 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DETAILED LIST OF CONFERENCES & EVENTS, 2022–2023 77
5.9 KEY STAKEHOLDERS AND BUYING CRITERIA 78
5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS 78
FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CDMO SERVICES 78
5.9.2 BUYING CRITERIA 78
FIGURE 25 KEY BUYING CRITERIA FOR END USERS 78
5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS 79
FIGURE 26 REVENUE SHIFT & NEW POCKETS FOR PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 79
5.11 ANDA APPROVALS 79
FIGURE 27 ANDA APPROVALS, 2018–2022 79
FIGURE 28 REGIONAL BREAKDOWN OF ANDA APPROVALS IN 2022 80
FIGURE 29 ANDA APPROVALS IN 2022, BY DOSAGE FORM 80
6 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE 81
6.1 INTRODUCTION 82
TABLE 15 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 82
6.2 PHARMACEUTICAL MANUFACTURING SERVICES 82
TABLE 16 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 83
TABLE 17 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION) 83
TABLE 18 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 83
TABLE 19 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 84
TABLE 20 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 84
TABLE 21 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 85
6.2.1 PHARMACEUTICAL API MANUFACTURING SERVICES 85
6.2.1.1 Need to focus on core areas to drive pharma companies to outsource API manufacturing 85
TABLE 22 PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION) 86
TABLE 23 NORTH AMERICA: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 86
TABLE 24 EUROPE: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 87
TABLE 25 ASIA PACIFIC: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 87
TABLE 26 LATIN AMERICA: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 88
6.2.2 PHARMACEUTICAL FDF MANUFACTURING SERVICES 88
TABLE 27 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 89
TABLE 28 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION) 89
TABLE 29 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 90
TABLE 30 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 90
TABLE 31 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 91
TABLE 32 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 91
6.2.2.1 Parenteral/Injectable manufacturing services 91
6.2.2.1.1 Increasing investments in drug development to support market growth 91
TABLE 33 PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION) 92
TABLE 34 NORTH AMERICA: PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 92
TABLE 35 EUROPE: PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 93
TABLE 36 ASIA PACIFIC: PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 93
TABLE 37 LATIN AMERICA: PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 94
6.2.2.2 Tablet manufacturing services 94
6.2.2.2.1 Growing production capacity for tablet manufacturing in emerging markets to support growth 94
TABLE 38 TABLET MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION) 94
TABLE 39 NORTH AMERICA: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 95
TABLE 40 EUROPE: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 95
TABLE 41 ASIA PACIFIC: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 96
TABLE 42 LATIN AMERICA: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 96
6.2.2.3 Capsule manufacturing services 96
6.2.2.3.1 Popularity of capsules to ensure demand for contract manufacturing 96
TABLE 43 CAPSULE MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION) 97
TABLE 44 NORTH AMERICA: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 97
TABLE 45 EUROPE: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 98
TABLE 46 ASIA PACIFIC: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 98
TABLE 47 LATIN AMERICA: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 99
6.2.2.4 Oral liquid manufacturing services 99
6.2.2.4.1 Complexities in handling liquids to promote outsourcing 99
TABLE 48 ORAL LIQUID MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION) 100
TABLE 49 NORTH AMERICA: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 100
TABLE 50 EUROPE: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 101
TABLE 51 ASIA PACIFIC: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 101
TABLE 52 LATIN AMERICA: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 102
6.2.2.5 Semi-solid manufacturing services 102
6.2.2.5.1 Need for specialized facilities to boost outsourcing of semi-solid manufacturing 102
TABLE 53 SEMI-SOLID MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION) 103
TABLE 54 NORTH AMERICA: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 103
TABLE 55 EUROPE: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 104
TABLE 56 ASIA PACIFIC: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 104
TABLE 57 LATIN AMERICA: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 105
6.2.2.6 Other FDF manufacturing services 105
TABLE 58 OTHER FDF MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION) 106
TABLE 59 NORTH AMERICA: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 106
TABLE 60 EUROPE: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 107
TABLE 61 ASIA PACIFIC: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 107
TABLE 62 LATIN AMERICA: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 108
6.3 DRUG DEVELOPMENT SERVICES 108
6.3.1 HIGH COST OF DEVELOPMENT TO BOOST OUTSOURCING 108
TABLE 63 DRUG DEVELOPMENT SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION) 109
TABLE 64 NORTH AMERICA: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 109
TABLE 65 EUROPE: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 110
TABLE 66 ASIA PACIFIC: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 110
TABLE 67 LATIN AMERICA: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 111
6.4 BIOLOGIC MANUFACTURING SERVICES 111
TABLE 68 BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 112
TABLE 69 BIOLOGIC MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION) 112
TABLE 70 NORTH AMERICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 112
TABLE 71 EUROPE: BIOLOGIC MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 113
TABLE 72 ASIA PACIFIC: BIOLOGIC MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 113
TABLE 73 LATIN AMERICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 114
6.4.1 BIOLOGIC API MANUFACTURING SERVICES 114
6.4.1.1 Rising interest in biologics to ensure growth of nascent contract manufacturing sector 114
TABLE 74 BIOLOGIC API MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION) 115
TABLE 75 NORTH AMERICA: BIOLOGIC API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 115
TABLE 76 EUROPE: BIOLOGIC API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 116
TABLE 77 ASIA PACIFIC: BIOLOGIC API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 116
TABLE 78 LATIN AMERICA: BIOLOGIC API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 117
6.4.2 BIOLOGIC FDF MANUFACTURING SERVICES 117
6.4.2.1 Growing R&D costs and process complexity to favor contract manufacturing 117
TABLE 79 BIOLOGIC FDF MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION) 117
TABLE 80 NORTH AMERICA: BIOLOGIC FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 118
TABLE 81 EUROPE: BIOLOGIC FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 118
TABLE 82 ASIA PACIFIC: BIOLOGIC FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 119
TABLE 83 LATIN AMERICA: BIOLOGIC FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 119
7 PHARMACEUTICAL CONTRACT DEVELOPMENT AND
MANUFACTURING MARKET, BY END USER 120
7.1 INTRODUCTION 121
TABLE 84 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 121
7.2 BIG PHARMACEUTICAL COMPANIES 121
7.2.1 EMERGENCE OF NEW MEDICINES AND THERAPIES TO CONTRIBUTE TO MARKET GROWTH 121
TABLE 85 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION) 122
TABLE 86 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION) 123
TABLE 87 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION) 123
TABLE 88 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION) 124
TABLE 89 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION) 124
7.3 SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES 124
7.3.1 GROWING DEVELOPMENT OF BIOLOGICS AND HIGH PRICING PRESSURE TO BOOST MARKET 124
TABLE 90 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY REGION, 2021–2028 (USD BILLION) 125
TABLE 91 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION) 126
TABLE 92 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION) 126
TABLE 93 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION) 127
TABLE 94 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION) 127
7.4 GENERIC PHARMACEUTICAL COMPANIES 127
7.4.1 RISING DEMAND FOR GENERICS TO PROPEL MARKET 127
TABLE 95 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY REGION, 2021–2028 (USD BILLION) 128
TABLE 96 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION) 128
TABLE 97 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION) 129
TABLE 98 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION) 129
TABLE 99 LATIN AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION) 130
7.5 OTHER END USERS 130
TABLE 100 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD BILLION) 130
TABLE 101 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD BILLION) 131
TABLE 102 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD BILLION) 131
TABLE 103 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD BILLION) 132
TABLE 104 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD BILLION) 132
8 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY REGION 133
8.1 INTRODUCTION 134
TABLE 105 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY REGION, 2021–2028 (USD BILLION) 134
8.2 NORTH AMERICA 134
FIGURE 30 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT 135
TABLE 106 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 136
TABLE 107 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 136
TABLE 108 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 136
TABLE 109 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 137
TABLE 110 NORTH AMERICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 137
TABLE 111 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 138
8.2.1 US 138
8.2.1.1 US to dominate North American market 138
TABLE 112 US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 139
TABLE 113 US: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 139
TABLE 114 US: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 140
TABLE 115 US: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 140
TABLE 116 US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 141
8.2.2 CANADA 141
8.2.2.1 Rising government funding and support to propel market 141
TABLE 117 CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 142
TABLE 118 CANADA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 142
TABLE 119 CANADA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 143
TABLE 120 CANADA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 143
TABLE 121 CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 144
8.2.3 NORTH AMERICA: RECESSION IMPACT 144
8.3 EUROPE 145
TABLE 122 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 145
TABLE 123 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 146
TABLE 124 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 146
TABLE 125 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 147
TABLE 126 EUROPE: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 147
TABLE 127 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 148
8.3.1 GERMANY 148
8.3.1.1 Germany to hold largest share throughout forecast period 148
TABLE 128 GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 149
TABLE 129 GERMANY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 149
TABLE 130 GERMANY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 150
TABLE 131 GERMANY: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 150
TABLE 132 GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 151
8.3.2 UK 151
8.3.2.1 Rising investments in drug development to favor market growth 151
TABLE 133 UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 152
TABLE 134 UK: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 152
TABLE 135 UK: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 153
TABLE 136 UK: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 153
TABLE 137 UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 154
8.3.3 FRANCE 154
8.3.3.1 Growing generics segment, favorable government policies, and growing clinical trials to drive market 154
TABLE 138 FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 155
TABLE 139 FRANCE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 155
TABLE 140 FRANCE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 156
TABLE 141 FRANCE: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 156
TABLE 142 FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 157
8.3.4 ITALY 157
8.3.4.1 Rising commercial drug development pipeline in Europe to favor market growth 157
TABLE 143 ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 158
TABLE 144 ITALY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 158
TABLE 145 ITALY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 159
TABLE 146 ITALY: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 159
TABLE 147 ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 160
8.3.5 SWITZERLAND 160
8.3.5.1 Growing pharmaceutical industry to support growth 160
TABLE 148 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 161
TABLE 149 SWITZERLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 161
TABLE 150 SWITZERLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 162
TABLE 151 SWITZERLAND: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 162
TABLE 152 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 163
8.3.6 POLAND 163
8.3.6.1 Increasing support for life science R&D to propel market 163
TABLE 153 POLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 164
TABLE 154 POLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 164
TABLE 155 POLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 165
TABLE 156 POLAND: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 165
TABLE 157 POLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 166
8.3.7 SPAIN 166
8.3.7.1 Rising R&D expenditure to boost market 166
TABLE 158 SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 167
TABLE 159 SPAIN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 167
TABLE 160 SPAIN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 168
TABLE 161 SPAIN: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 168
TABLE 162 SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 169
8.3.8 REST OF EUROPE 169
TABLE 163 REST OF EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 170
TABLE 164 REST OF EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 170
TABLE 165 REST OF EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 171
TABLE 166 REST OF EUROPE: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 171
TABLE 167 REST OF EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 172
8.3.9 EUROPE: RECESSION IMPACT 172
8.4 ASIA PACIFIC 173
FIGURE 31 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT 174
TABLE 168 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 175
TABLE 169 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 175
TABLE 170 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 175
TABLE 171 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 176
TABLE 172 ASIA PACIFIC: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 176
TABLE 173 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 177
8.4.1 CHINA 177
8.4.1.1 China to hold largest share of Asia Pacific market 177
TABLE 174 CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 178
TABLE 175 CHINA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 178
TABLE 176 CHINA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 179
TABLE 177 CHINA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 179
TABLE 178 CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 180
8.4.2 INDIA 180
8.4.2.1 Increasing pharma R&D activities and government funding for biotechnology to support market growth 180
TABLE 179 INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 181
TABLE 180 INDIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 181
TABLE 181 INDIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 182
TABLE 182 INDIA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 182
TABLE 183 INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 183
8.4.3 JAPAN 183
8.4.3.1 Growing generics demand and government initiatives to drive demand for contract manufacturing 183
TABLE 184 JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 184
TABLE 185 JAPAN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 184
TABLE 186 JAPAN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 185
TABLE 187 JAPAN: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 185
TABLE 188 JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 186
8.4.4 SOUTH KOREA 186
8.4.4.1 Government initiatives and growing R&D activities for drug development to drive market growth 186
TABLE 189 SOUTH KOREA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 187
TABLE 190 SOUTH KOREA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 187
TABLE 191 SOUTH KOREA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 188
TABLE 192 SOUTH KOREA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 188
TABLE 193 SOUTH KOREA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 189
8.4.5 REST OF ASIA PACIFIC 189
TABLE 194 REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 190
TABLE 195 REST OF ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 190
TABLE 196 REST OF ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 191
TABLE 197 REST OF ASIA PACIFIC: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 191
TABLE 198 REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 192
8.4.6 ASIA PACIFIC: RECESSION IMPACT 192
8.5 LATIN AMERICA 193
TABLE 199 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 193
TABLE 200 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 193
TABLE 201 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 194
TABLE 202 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 194
TABLE 203 LATIN AMERICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 194
TABLE 204 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 195
8.5.1 BRAZIL 195
8.5.1.1 Growing pharmaceutical industry to drive market 195
TABLE 205 BRAZIL: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 196
TABLE 206 BRAZIL: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 196
TABLE 207 BRAZIL: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 196
TABLE 208 BRAZIL: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 197
TABLE 209 BRAZIL: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 197
8.5.2 REST OF LATIN AMERICA 197
TABLE 210 REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 198
TABLE 211 REST OF LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 198
TABLE 212 REST OF LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 199
TABLE 213 REST OF LATIN AMERICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 199
TABLE 214 REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 200
8.5.3 LATIN AMERICA: RECESSION IMPACT 200
8.6 MIDDLE EAST & AFRICA 201
8.6.1 UAE AND SAUDI ARABIA TO SHOW SIGNIFICANT GROWTH 201
TABLE 215 MIDDLE EAST & AFRICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 201
TABLE 216 MIDDLE EAST & AFRICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 202
TABLE 217 MIDDLE EAST & AFRICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 202
TABLE 218 MIDDLE EAST & AFRICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 203
TABLE 219 MIDDLE EAST & AFRICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 203
8.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 203
9 COMPETITIVE LANDSCAPE 204
9.1 OVERVIEW 204
9.2 KEY PLAYER STRATEGIES 204
TABLE 220 KEY STRATEGIES ADOPTED BY PLAYERS IN PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, 2020–2023 204
9.3 REVENUE SHARE ANALYSIS 206
FIGURE 32 REVENUE SHARE ANALYSIS OF KEY PLAYERS, 2020–2022 206
9.4 MARKET SHARE ANALYSIS 207
FIGURE 33 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022 207
TABLE 221 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DEGREE OF COMPETITION 207
9.5 COMPANY EVALUATION QUADRANT FOR KEY PLAYERS, 2022 208
9.5.1 STARS 208
9.5.2 EMERGING LEADERS 208
9.5.3 PERVASIVE PLAYERS 209
9.5.4 PARTICIPANTS 209
FIGURE 34 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: COMPANY EVALUATION QUADRANT, 2022 209
9.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 210
9.6.1 SERVICE FOOTPRINT OF COMPANIES (25 COMPANIES) 210
TABLE 222 SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS IN PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 210
9.6.2 END-USER FOOTPRINT OF COMPANIES (25 COMPANIES) 211
TABLE 223 END-USER FOOTPRINT ANALYSIS OF KEY PLAYERS IN PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 211
9.6.3 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES) 213
TABLE 224 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 213
9.7 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES (2022) 214
9.7.1 PROGRESSIVE COMPANIES 214
9.7.2 STARTING BLOCKS 214
9.7.3 RESPONSIVE COMPANIES 214
9.7.4 DYNAMIC COMPANIES 214
FIGURE 35 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES, 2022 215
9.8 COMPETITIVE BENCHMARKING OF START-UPS/SMES 215
TABLE 225 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS 215
TABLE 226 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 216
9.9 COMPETITIVE SCENARIO AND TRENDS 217
9.9.1 SERVICE LAUNCHES 217
TABLE 227 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: SERVICE LAUNCHES, JANUARY 2020–MARCH 2023 217
9.9.2 DEALS 217
TABLE 228 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DEALS, JANUARY 2020–MARCH 2023 217
9.9.3 OTHER DEVELOPMENTS 218
TABLE 229 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: OTHER DEVELOPMENTS, JANUARY 2020–MARCH 2023 218
10 COMPANY PROFILES 219
10.1 KEY MARKET PLAYERS 219
(Business Overview, Services Offered, Recent Developments, and MnM View)*
10.1.1 THERMO FISHER SCIENTIFIC, INC. 219
TABLE 230 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 219
FIGURE 36 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022) 220
10.1.2 CATALENT, INC. 223
TABLE 231 CATALENT, INC.: BUSINESS OVERVIEW 223
FIGURE 37 CATALENT, INC.: COMPANY SNAPSHOT (2022) 224
10.1.3 LONZA GROUP 231
TABLE 232 LONZA GROUP: BUSINESS OVERVIEW 231
FIGURE 38 LONZA GROUP: COMPANY SNAPSHOT (2022) 232
10.1.4 ABBVIE, INC. 237
TABLE 233 ABBVIE, INC.: BUSINESS OVERVIEW 237
FIGURE 39 ABBVIE, INC.: COMPANY SNAPSHOT (2022) 238
10.1.5 WUXI APPTEC 240
TABLE 234 WUXI APPTEC: BUSINESS OVERVIEW 240
FIGURE 40 WUXI APPTEC: COMPANY SNAPSHOT (2022) 241
10.1.6 EVONIK INDUSTRIES AG 243
TABLE 235 EVONIK INDUSTRIES AG: BUSINESS OVERVIEW 243
FIGURE 41 EVONIK INDUSTRIES AG: COMPANY SNAPSHOT (2022) 244
10.1.7 SAMSUNG BIOLOGICS 246
TABLE 236 SAMSUNG BIOLOGICS: BUSINESS OVERVIEW 246
FIGURE 42 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2022) 246
10.1.8 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 249
TABLE 237 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: BUSINESS OVERVIEW 249
FIGURE 43 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2022) 250
10.1.9 SIEGFRIED HOLDING AG 252
TABLE 238 SIEGFRIED HOLDING AG: BUSINESS OVERVIEW 252
FIGURE 44 SIEGFRIED HOLDING AG: COMPANY SNAPSHOT (2022) 252
10.1.10 FUJIFILM HOLDINGS CORPORATION 254
TABLE 239 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW 254
FIGURE 45 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022) 255
10.1.11 EUROFINS SCIENTIFIC 258
TABLE 240 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW 258
FIGURE 46 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022) 258
10.1.12 PIRAMAL PHARMA SOLUTIONS 261
TABLE 241 PIRAMAL PHARMA SOLUTIONS: BUSINESS OVERVIEW 261
FIGURE 47 PIRAMAL PHARMA SOLUTIONS: COMPANY SNAPSHOT (2022) 262
10.1.13 RECIPHARM AB 265
TABLE 242 RECIPHARM AB: BUSINESS OVERVIEW 265
10.1.14 ALMAC GROUP 268
TABLE 243 ALMAC GROUP: BUSINESS OVERVIEW 268
10.1.15 VETTER PHARMA 270
TABLE 244 VETTER PHARMA: BUSINESS OVERVIEW 270
* Business Overview, Services Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
10.2 OTHER PLAYERS 272
10.2.1 DELPHARM HOLDINGS 272
10.2.2 YUHAN CORPORATION 273
10.2.3 CURIA GLOBAL, INC. 274
10.2.4 CHARLES RIVER LABORATORIES 275
10.2.5 LANNETT COMPANY, INC. 276
10.2.6 CAMBREX CORPORATION 277
10.2.7 FAMAR HEALTHCARE SERVICES 278
10.2.8 SYNGENE INTERNATIONAL LIMITED (BIOCON LIMITED) 279
10.2.9 SAI LIFE SCIENCES LIMITED 280
10.2.10 PCI PHARMA SERVICES 281
11 APPENDIX 282
11.1 DISCUSSION GUIDE 282
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 286
11.3 CUSTOMIZATION OPTIONS 288
11.4 RELATED REPORTS 288
11.5 AUTHOR DETAILS 289